Search alternatives:
significantly linear » significant linear (Expand Search), significantly lower (Expand Search), significantly longer (Expand Search)
linear decrease » linear increase (Expand Search)
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
significantly linear » significant linear (Expand Search), significantly lower (Expand Search), significantly longer (Expand Search)
linear decrease » linear increase (Expand Search)
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
-
2121
-
2122
-
2123
-
2124
-
2125
-
2126
-
2127
-
2128
-
2129
-
2130
-
2131
-
2132
-
2133
-
2134
Study data.
Published 2025“…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”
-
2135
Summary of clinical outcomes after 9 months.
Published 2025“…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”
-
2136
Approval by the research ethics committee.
Published 2025“…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”
-
2137
-
2138
-
2139
-
2140
Risk Illustration.
Published 2025“…Similarly, patients with EF > 40% had decreased incidence of SCD compared to those with EF < 40% (HR 0.347, 95% CI:0.158–0.763; p = 0.008). …”